tcl: rationale and overview of the phase 3 alcanza trial
Published 7 years ago • 21 plays • Length 2:44Download video MP4
Download video MP3
Similar videos
-
1:31
dr. moskowitz on the alcanza trial in ctcl
-
0:46
alcanza: brentuximab vedotin improves orr and pfs in ctcl
-
3:00
primary cutaneous t-cell lymphoma: alcanza trial
-
4:52
phase iii echelon-1 study: updated results of brentuximab vedotin chemotherapy for untreated chl
-
6:08
what is early data telling us about the potential of oncolytic virotherapy for patients with tcl?
-
5:49
tcl foldable and rollable concept devices at mwc 2022
-
55:04
insulin resistance, weight management, and eating optimally with dr. mitch roslin
-
1:33:52
ending tb: right dose, right time
-
4:17
efficacy of brentuximab vedotin in treating cutaneous t-cell lymphoma
-
5:13
improving safety and efficacy with brentuximab vedotin, nivolumab and ad for advanced stage chl.
-
1:09
an aggressive resection
-
4:00
differences in presentation of ctcl (chapter 3)
-
2:46
alcanza: brentuximab vedotin for ctcl
-
5:15
gallium phase iii trial in follicular lymphoma
-
1:57
key trials in ctcl
-
1:57
new! multi-valve surgery risk calculator
-
0:58
approval of brentuximab vedotin for cd30 mycosis fungoides
-
1:09
dr. fowler on flipi scoring system in follicular lymphoma
-
2:58
a case of mtc features and spindle cells
-
2:44
brentuximab vedotin and chp for ptcl: upcoming phase ii trial
-
5:11
the aethera trial: risk of progression following asc transplant for hodgkin lymphoma
-
1:15
risk stratification for ctcl